IL-4/IL-13 pathway in nasal type 2 inflammation: The central role and targeted therapy

Abstract

Type 2 dominant inflammation in nasal mucosa is the key underlying pathophysiological mechanism of allergic rhinitis (AR) and most presentations of chronic rhinosinusitis with nasal polyps (CRSwNP). Interleukin-4 (IL-4) and IL-13 share common receptor subunits and signaling molecules, which lead to various pathological changes in different cells, playing key roles in the pathogenesis of nasal type 2 inflammation. Numerous clinical trials have shown that biologics targeting key molecules of the IL-4/IL-13 pathway, especially IL-4 receptor alpha, can treat CRSwNP and AR with high efficacy, and are generally well tolerated. Several biologics have been approved for the treatment of difficult-to-control CRSwNP, while others also show promising results. Here, we review the IL-4/IL-13 pathway, its role in nasal type 2 inflammation, and current targeted therapies related to the IL-4/IL-13 pathway, with a focus on AR and CRSwNP.

Keywords

biologic / IL-13 / IL-4 / nasal type 2 inflammation

References

[1] Bousquet J, Toumi M, Sousa-Pinto B, et al. The allergic rhinitis and its impact on asthma (ARIA) Approach of value-added medicines: as-needed treatment in allergic rhinitis. J Allergy Clin Immunol Pract. 2022;10(11):2878-2888.

[2] Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis. Nat Rev Dis Prim. 2020;6(1):95.

[3] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.

[4] Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312-2319.

[5] Shi JB, Fu QL, Zhang H, et al. Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy. 2015;70(5):533-539.

[6] Cox L. Approach to patients with allergic rhinitis: testing and treatment. Med Clin. 2020;104(1):77-94.

[7] Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650.

[8] Zhang Y, Lan F, Zhang L. Update on pathomechanisms and treatments in allergic rhinitis. Allergy. 2022;77(11):3309-3319.

[9] Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of allergy and clinical Immunology and the American Academy of allergy, asthma and Immunology. J allergy Clin Immunol. 2013;131(6):1479-1490.

[10] Cornet ME, Kostamo K, Rinia AB, et al. Novel roles for nasal epithelium in the pathogenesis of chronic rhinosinusitis with nasal polyps. Rhinology. 2019;57(3):169-179.

[11] Toppila-Salmi S, van Drunen CM, Fokkens WJ, et al. Molecular mechanisms of nasal epithelium in rhinitis and rhinosinusitis. Curr Allergy Asthma Rep. 2015;15(2):495.

[12] Kato A. Immunopathology of chronic rhinosinusitis. Allergology Int. 2015;64(2):121-130.

[13] Jenerowicz D, Silny W, Danczak-Pazdrowska A, Polanska A, Osmola-Mankowska A, Olek-Hrab K. Environmental factors and allergic diseases. Ann Agric Environ Med. 2012;19(3):475-481.

[14] Guilleminault L, Conde E, Reber LL. Pharmacological approaches to target type 2 cytokines in asthma. Pharmacol Ther. 2022;237:108167.

[15] Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15(5):271-282.

[16] Miljkovic D, Bassiouni A, Cooksley C, et al. Association between group 2 innate lymphoid cells enrichment, nasal polyps and allergy in chronic rhinosinusitis. Allergy. 2014;69(9):1154-1161.

[17] Shaw JL, Fakhri S, Citardi MJ, et al. IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med. 2013;188(4):432-439.

[18] Gao S, Zeng Q, Zeng Y, Tang Y, Liu W. High density lipoprotein inhibited group II innate lymphoid cells proliferation and function in allergic rhinitis. Allergy Asthma Clin Immunol. 2022;18(1):40.

[19] Gauvreau GM, Bergeron C, Boulet LP, et al. Sounding the alarmins -the role of alarmin cytokines in asthma. Allergy. 2023;78(2):402-417.

[20] Porsbjerg CM, Sverrild A, Lloyd CM, Menzies-Gow AN, Bel EH. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260.

[21] Walker JA, McKenzie ANJ. T(H)2 cell development and function. Nat Rev Immunol. 2018;18(2):121-133.

[22] Zhong H, Fan XL, Yu QN, et al. Increased innate type 2 immune response in house dust mite-allergic patients with allergic rhinitis. Clin Immunol. 2017;183:293-299.

[23] Shin SH, Ye MK, Park J, Geum SY. Immunopathologic role of eosinophils in eosinophilic chronic rhinosinusitis. Int J Mol Sci. 2022;23(21):13313.

[24] Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J allergy Clin Immunol. 2011;128(5):989-995.

[25] Bachert C, Sousa AR, Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol. 2022;149(5):1711-1721.

[26] Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141-1153.

[27] Zhu JT. Helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. 2015;75(1):14-24.

[28] Song Z, Yuan W, Zheng L, et al. B cell IL-4 drives Th2 responses in vivo, ameliorates allograft rejection, and promotes allergic airway disease. Front Immunol. 2022;13:762390.

[29] Chapoval S, Dasgupta P, Dorsey NJ, Keegan AD. Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol. 2010;87(6):1011-1018.

[30] Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol. 2012;130(4):829-842. quiz 843-824.

[31] Wang X, Xu C, Ji J, et al. IL-4/IL-13 upregulates Sonic hedgehog expression to induce allergic airway epithelial remodeling. Am J Physiol Lung Cell Mol Physiol. 2020;318(5):L888-L899.

[32] Zhang Y, Derycke L, Holtappels G, et al. Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL-5-positive chronic rhinosinusitis with nasal polyps. Allergy. 2019;74(1):131-140.

[33] Zhang Y, Wang X, Wang H, et al. TMEM16A-Mediated mucin secretion in IL-13-induced nasal epithelial cells from chronic rhinosinusitis patients. Allergy Asthma Immunol Res. 2015;7(4):367-375.

[34] Wang MJ, Kang MX, Huang MZQ, et al. Protease-activated receptor-2 decreased zonula occlidens-1 and claudin-1 expression and induced epithelial barrier dysfunction in allergic rhinitis. American J Rhinol Allergy. 2021;35(1):26-35.

[35] Jiao J, Wang C, Zhang L. Epithelial physical barrier defects in chronic rhinosinusitis. Expet Rev Clin Immunol. 2019;15(6):679-688.

[36] Jiao J, Duan S, Meng N, Li Y, Fan E, Zhang L. Role of IFN-γ IL-13, and IL-17 on mucociliary differentiation of nasal epithelial cells in chronic rhinosinusitis with nasal polyps. Clin Exp Allergy. 2016;46(3):449-460.

[37] Martinez-Anton A, Debolos C, Garrido M, et al. Mucin genes have different expression patterns in healthy and diseased upper airway mucosa. Clin Exp Allergy. 2006;36(4):448-457.

[38] Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S73-S80.

[39] Chen JB, James LK, Davies AM, et al. Antibodies and superantibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017;139(4):1195-1204.e1111.

[40] Lan F, Zhang N, Holtappels G, et al. Staphylococcus aureus induces a mucosal type 2 immune response via epithelial cell-derived cytokines. Am J Respir Crit Care Med. 2018;198(4):452-463.

[41] McKenzie AN, Li X, Largaespada DA, et al. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol. 1993;150(12):5436-5444.

[42] Keegan AD, Leonard WJ, Zhu J. Recent advances in understanding the role of IL-4 signaling. Faculty Rev. 2021;10:71.

[43] Zhu L, Zhao Q, Yang T, Ding W, Zhao Y. Cellular metabolism and macrophage functional polarization. Int Rev Immunol. 2015;34(1):82-100.

[44] Shankar A, McAlees JW, Lewkowich IP. Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease. J Allergy Clin Immunol. 2022;150(2):266-276.

[45] Paul WE. History of interleukin-4. Cytokine. 2015;75(1):3-7.

[46] Kariyawasam HH, James LK, Gane SB. Dupilumab: clinical efficacy of blocking IL-4/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Dev Ther. 2020;14:1757-1769.

[47] Pelaia C, Crimi C, Vatrella A, Tinello C, Terracciano R, Pelaia G. Molecular targets for biological therapies of severe asthma. Front Immunol. 2020;11:603312.

[48] Ul-Haq Z, Naz S, Mesaik MA. Interleukin-4 receptor signaling and its binding mechanism: a therapeutic insight from inhibitors tool box. Cytokine Growth Factor Rev. 2016;32:3-15.

[49] Bartolomé RA, Jaén M, Casal JI. An IL13Rα2 peptide exhibits therapeutic activity against metastatic colorectal cancer. Br J Cancer. 2018;119(8):940-949.

[50] Marone G, Granata F, Pucino V, et al. The intriguing role of interleukin 13 in the pathophysiology of asthma. Front Pharmacol. 2019;10:1387.

[51] Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50(1):5-14.

[52] Leonard WJ, Lin JX, O’Shea JJ. The gamma(c) family of cytokines: basic biology to therapeutic ramifications. Immunity. 2019;50(4):832-850.

[53] Wang HY, Zamorano J, Keegan AD. A role for the insulininterleukin (IL)-4 receptor motif of the IL-4 receptor alphachain in regulating activation of the insulin receptor substrate 2 and signal transducer and activator of transcription 6 path-ways. Analysis by mutagenesis. J Biol Chem. 1998;273(16):9898-9905.

[54] Heller NM, Qi X, Junttila IS, et al. Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. Sci Signal. 2008;1(51):ra17.

[55] Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008;27(50):6473-6488.

[56] McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine. 2015;75(1):38-50.

[57] Nguyen JK, Austin E, Huang A, Mamalis A, Jagdeo J. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Archives Dermatol Res. 2020;312(2):81-92.

[58] Karpathiou G, Papoudou-Bai A, Ferrand E, Dumollard JM, Peoc’h M. STAT6: a review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology. Pathol Res Pract. 2021;223:153477.

[59] Kraich M, Klein M, Patiño E, et al. A modular interface of IL-4 allows for scalable affinity without affecting specificity for the IL-4 receptor. BMC Biol. 2006;4(1):13.

[60] Lupardus PJ, Birnbaum ME, Garcia KC. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Rα2. Structure. 2010;18(3):332-342.

[61] Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888.

[62] Xu X, Li J, Zhang Y, Zhang L. Arachidonic acid 15-lipoxygenase: effects of its expression, metabolites, and genetic and epigenetic variations on airway inflammation. Allergy Asthma Immunol Res. 2021;13(5):684-696.

[63] Ogulur I, Pat Y, Ardicli O, et al. Advances and highlights in biomarkers of allergic diseases. Allergy. 2021;76(12):3659-3686.

[64] Liang J, Zhuang R, Sun X, Zhang F, Zou B. Apremilast mitigates interleukin (IL)-13-induced inflammatory response and mucin production in human nasal epithelial cells (hNECs). Bioengineered. 2021;12(1):8583-8593.

[65] Massey O, Suphioglu C. Recent advances in the inhibition of the IL-4 cytokine pathway for the treatment of allergen-induced asthma. Int J Mol Sci. 2021;22(24):13655.

[66] Akdis CA, Arkwright PD, Bruggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.

[67] Kariyawasam HH. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab. Expet Rev Clin Immunol. 2020;16(12):1115-1125.

[68] Maspero J, Adir Y, Al-Ahmad M, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3):00576-02021.

[69] Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expet Rev Clin Immunol. 2017;13(5):425-437.

[70] Movahedi M, Amirzargar AA, Nasiri R, et al. Gene polymorphisms of Interleukin-4 in allergic rhinitis and its association with clinical phenotypes. Am J Otolaryngol. 2013;34(6):676-681.

[71] Cutrina-Pons A, De Sa A, Fear DJ, Gould HJ, Ramadani F. Inhibition of PI3K p110delta activity reduces IgE production in IL-4 and anti-CD40 stimulated human B cell cultures. Immunology. 2023;170(4):483-494.

[72] McLeod JJ, Baker B, Ryan JJ. Mast cell production and response to IL-4 and IL-13. Cytokine. 2015;75(1):57-61.

[73] Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: a review of present indications and off-label uses. J Investig Allergol Clin Immunol. 2022;32(2):97-115.

[74] Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188-1204.

[75] Gartner Y, Bitar L, Zipp F, Vogelaar CF. Interleukin-4 as a therapeutic target. Pharmacol Ther. 2023;242:108348.

[76] Nagata M, Nakagome K, Soma T. Mechanisms of eosinophilic inflammation. Asia Pac Allergy. 2020;10(2):e14.

[77] Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022;149(5):1491-1503.

[78] Chen J, Chen S, Gong G, Yang F, Chen J, Wang Y. Inhibition of IL-4/STAT6/IRF4 signaling reduces the epithelial-mesenchymal transition in eosinophilic chronic rhinosinusitis with nasal polyps. Int Immunopharm. 2023;121:110554.

[79] Huang SC, Smith AM, Everts B, et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling Axis is essential for macrophage alternative activation. Immunity. 2016;45(4):817-830.

[80] Takabayashi T, Kato A, Peters AT, et al. Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. Am J Respir Crit Care Med. 2013;187(1):49-57.

[81] Xuan L, Zhang N, Wang X, Zhang L, Bachert C. IL-10 family cytokines in chronic rhinosinusitis with nasal polyps: from experiments to the clinic. Front Immunol. 2022;13:947983.

[82] Sharma M, Leung D, Momenilandi M, et al. Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease. J Exp Med. 2023;220(5):e20221755.

[83] Lamiable O, Brewerton M, Ronchese F. IL-13 in dermal type-2 dendritic cell specialization: from function to therapeutic targeting. Eur J Immunol. 2022;52(7):1047-1057.

[84] Duan S, Han X, Jiao J, et al. Histone deacetylase activity is a novel target for epithelial barrier defects in patients with eosinophilic chronic rhinosinusitis with nasal polyps. Clin Exp Allergy. 2023;53(4):443-454.

[85] Steelant B, Seys SF, Van Gerven L, et al. Histamine and T helper cytokine-driven epithelial barrier dysfunction in allergic rhinitis. J Allergy Clin Immunol. 2018;141(3):951-963.e958.

[86] Kleuskens MTA, Haasnoot ML, Herpers BM, et al. Butyrate and propionate restore interleukin 13-compromised esophageal epithelial barrier function. Allergy. 2022;77(5):1510-1521.

[87] Yuan T, Zheng R, Liu J, et al. Role of yes-associated protein in interleukin-13 induced nasal remodeling of chronic rhinosinusitis with nasal polyps. Allergy. 2021;76(2):600-604.

[88] Magnolo N, Kingo K, Laquer V, et al. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2022;86(1):122-130.

[89] Catley MC, Coote J, Bari M, Tomlinson KL. Monoclonal antibodies for the treatment of asthma. Pharmacol Therapeut. 2011;132(3):333-351.

[90] Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(3 Suppl 1):S28-s36.

[91] Canonica GW, Bourdin A, Peters AT, et al. Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases. J Allergy Clin Immunol Pract. 2022;10(6):1515-1526.

[92] Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91-101.

[93] Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10(1):11-25.

[94] Zaazouee MS, Alwarraqi AG, Mohammed YA, et al. Dupilumab efficacy and safety in patients with moderate to severe asthma: a systematic review and meta-analysis. Front Pharmacol. 2022;13:992731.

[95] Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network metaanalysis. J Allergy Clin Immunol. 2022;149(4):1286-1295.

[96] Hoy SM. Dupilumab: a review in chronic rhinosinusitis with nasal polyps. Drugs. 2020;80(7):711-717.

[97] Mullur J, Steger CM, Gakpo D, et al. Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience. Ann Allergy Asthma Immunol. 2022;128(5):575-582.

[98] Wangberg H, Spierling Bagsic SR, Osuna L, White AA. Appraisal of the real-world effectiveness of biologic therapies in aspirinexacerbated respiratory disease. J Allergy Clin Immunol Pract. 2022;10(2):478-484.

[99] Bellocchi G, Loperfido A, Passali FM, et al. Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: a bicentric experience. Acta Biomed. 2023;94(5):e2023227.

[100] Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469-479.

[101] Mullol J, Bachert C, Amin N, et al. Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2022;10(4):1086-1095.e1085.

[102] Chen J, Wang H, Zhang C, et al. Comparative short-term efficacy of endoscopic sinus surgery and biological therapies in chronic rhinosinusitis with nasal polyps: a network meta-analysis. Clin Transl Allergy. 2023;13(6):e12269.

[103] Jeon HS, Jang JH, Lee Y, Park HS. Long-term efficacy of anti-IL-4 receptor antibody in a patient with aspirin-exacerbated respiratory disease and IgG4-related disease. Allergy Asthma Clin Immunol. 2023;19(1):67.

[104] Haxel BR, Hummel T, Fruth K, et al. Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. Rhinology. 2022;60(6):435-443.

[105] Dominguez-Ortega J, Mullol J, Alvarez Gutierrez FJ, et al. The effect of biologics in lung function and quality of life of patients with united airways disease: a systematic review. J Allergy Clin Immunol Glob. 2024;3(1):100174.

[106] Weinstein SF, Katial R, Jayawardena S, et al. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018;142(1):171-177.e171.

[107] Busse WW, Maspero JF, Lu Y, et al. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020;125(5):565-576.e561.

[108] Campion NJ, Doralt A, Lupinek C, et al. Dupilumab reduces symptom burden in allergic rhinitis and suppresses allergenspecific IgE production. Allergy. 2023;78(6):1687-1691.

[109] Corren J, Saini SS, Gagnon R, et al. Short-term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: a randomized trial. J Asthma Allergy. 2021;14:1045-1063.

[110] Kamal MA, Franchetti Y, Lai CH, et al. Pharmacokinetics and concentration-response of dupilumab in patients with seasonal allergic rhinitis. J Clin Pharmacol. 2022;62(5):689-695.

[111] Tao Z, Liu W, Chen Q, et al. Blocking Th2 signaling pathway alleviates the clinical symptoms and inflammation in allergic conjunctivitis. Invest Ophthalmol Vis Sci. 2023;64(10):30.

[112] Zhao Y, Zhang J, Yang B, et al. Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2b trial. Chin Med J. 2023.

[113] Zhang Y, Yan B, Shen S, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebocontrolled phase 2 clinical trial. EClinicalMedicine. 2023;61:102076.

[114] Zhang L, Ding Y, Wang Q, et al. Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Ralpha, for the treatment of Th2 inflammatory diseases. Sci Rep. 2023;13(1):12411.

[115] Wang J, White J, Sansone KJ, et al. Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Ralpha: two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clin Transl Sci. 2023;16(12):2614-2627.

[116] Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273-282.

[117] Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 2020;75(1):148-157.

[118] Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):990-1004.

[119] Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496.

[120] Buchheit KM, Sohail A, Hacker J, et al. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirinexacerbated respiratory disease. J Allergy Clin Immunol. 2022;150(2):415-424.

[121] Wang J, White J, Sansone KJ, et al. Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4Rα: two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Clin Transl Sci. 2023;16(12):2614-2627.

[122] Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450-463.

[123] Panettieri RA, Jr., Sjöbring U, Péterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018;6(7):511-525.

[124] Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080-1091.

[125] Szefler SJ, Roberts G, Rubin AS, et al. Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS). Clin Transl Allergy. 2022;12(7):e12176.

[126] Chaker AM, Shamji MH, Dumitru FA, et al. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: a randomized controlled trial. J Allergy Clin Immunol. 2016;137(2):452-461.e459.

[127] Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002;130(1):93-100.

[128] Book R, Eligal S, Tal Y, Eliashar R. Biological treatment for uncontrolled chronic rhinosinusitis with nasal polyps: preliminary real-world results from a tertiary medical center. J Clin Med. 2023;12(11):3671.

[129] De Corso E, Settimi S, Montuori C, et al. Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: a “Real-Life” observational study in the first year of treatment. J Clin Med. 2022;11(10):2684.

[130] Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725-739.

[131] Tang R, Lei S, Zhu L, Lv Y, Li H. Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study. Front Immunol. 2022;13:913424.

RIGHTS & PERMISSIONS

2024 The Authors. Eye & ENT Research published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.